Findings on the Burdens of Diabetic Peripheral Neuropathic Pain (DPNP) Among Three Lexicon-Sponsored Presentations at the 84th Scientific Sessions of the American Diabetes Association
14 Juin 2024 - 2:00PM
Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced
that three poster presentations will be delivered during the 84th
Scientific Sessions of the American Diabetes Association being held
June 21 - 24, 2024 at the Orange County Convention Center in
Orlando, Florida.
All three poster presentations will occur on Sunday, June 23,
12:30 - 1:30 p.m. ET, in the Poster Hall (West A-4-B2). Details are
as follows:
- "Patient-Reported Burden of Disease in Diabetic
Peripheral Neuropathic Pain—Learnings from In-depth Patient
Interviews—Substudy of RELIEF-DPN 1," Board No. 484,
presented by Linda M. Gaudiani MD, FACP, FACE, Medical Director and
President NorCal Medical Research, Greenbrae, California,
Co-Founder Braden Diabetes Center and President Marin Endocrine
Care and Research Greenbrae, California
- “Impact of Sotagliflozin, a Dual Sodium–Glucose
Cotransporter 1/2 Inhibitor, as Add-on to Inadequately Controlled
Basal Insulin–Treated Type 2 Diabetes,” Board No. 924,
presented by Julio Rosenstock, MD, Senior Scientific Advisor for
Velocity Clinical Research, Director of Velocity’s site at Medical
City Dallas, and Clinical Professor of Medicine at the University
of Texas Southwestern Medical Center, Dallas, Texas
- “Sotagliflozin vs. Empagliflozin or Placebo in Type 2
Diabetes on a DPP-4i +/- Metformin,” Board No. 917,
presented by Anne L. Peters, MD, Professor of Medicine at the Keck
School of Medicine of USC, Director of the USC Clinical Diabetes
Programs, Los Angeles, California
“The Lexicon-sponsored research to be presented reflect our
ongoing commitment to addressing unmet medical needs within the
diabetes community,” said Craig Granowitz, M.D., Ph.D., Lexicon’s
senior vice president and chief medical officer. “We are especially
appreciative of the people with diabetes who shared their
first-hand and deeply personal accounts of the tremendous burdens
associated with diabetic peripheral neuropathic pain.”
About Lexicon PharmaceuticalsLexicon is a
biopharmaceutical company with a mission of pioneering medicines
that transform patients’ lives. Through the Genome5000™ program,
Lexicon’s unique genomics target discovery platform, Lexicon
scientists studied the role and function of nearly 5,000 genes and
identified more than 100 protein targets with significant
therapeutic potential in a range of diseases. Through the precise
targeting of these proteins, Lexicon is pioneering the discovery
and development of innovative medicines to treat disease safely and
effectively. Lexicon has commercially launched one of these
medicines, INPEFA® (sotagliflozin) in the United States, and has a
pipeline of other promising drug candidates in discovery and
clinical and preclinical development in neuropathic pain, diabetes
and metabolism and other indications. For additional information,
please visit www.lexpharma.com.
About LX9211
Discovered using Lexicon’s unique approach to
gene science, LX9211 is a potent, orally delivered, selective,
investigational small molecule inhibitor of adaptor-associated
kinase 1 (AAK1). Lexicon identified AAK1 in its target discovery
efforts as a promising approach for the treatment of neuropathic
pain and identified LX9211 and another development candidate in a
neuroscience drug discovery alliance with Bristol-Myers Squibb from
which Lexicon holds exclusive development and commercialization
rights. Preclinical studies of LX9211 demonstrated central nervous
system penetration and reduction in pain behavior in models of
neuropathic pain without affecting opiate pathways. LX9211 has
received Fast Track designation from the U.S. Food and Drug
Administration for development in diabetic peripheral neuropathic
pain.
About Sotagliflozin
Discovered using Lexicon’s unique approach to
gene science, sotagliflozin is an oral inhibitor of two proteins
responsible for glucose regulation known as sodium-glucose
cotransporter types 2 and 1 (SGLT2 and SGLT1). SGLT2 is responsible
for glucose and sodium reabsorption by the kidney and SGLT1 is
responsible for glucose and sodium absorption in the
gastrointestinal tract. Sotagliflozin has been studied in multiple
patient populations encompassing heart failure, diabetes, and
chronic kidney disease in clinical studies involving approximately
20,000 patients.
Safe Harbor Statement
This press release contains “forward-looking
statements,” including statements relating to Lexicon’s financial
position and long-term outlook on its business, growth and future
operating results, discovery, development and commercialization of
products, strategic alliances and intellectual property, as well as
other matters that are not historical facts or information. All
forward-looking statements are based on management’s current
assumptions and expectations and involve risks, uncertainties and
other important factors, specifically including Lexicon’s ability
to meet its capital requirements, successfully commercialize INPEFA
in heart failure, conduct preclinical and clinical development and
obtain necessary regulatory approvals of sotagliflozin (in other
indications), LX9211, LX9851 and its other drug candidates on its
anticipated timelines, achieve its operational objectives, obtain
patent protection for its discoveries and establish strategic
alliances, as well as additional factors relating to manufacturing,
intellectual property rights, and the therapeutic or commercial
value of its products and drug candidates. Any of these risks,
uncertainties and other factors may cause Lexicon’s actual results
to be materially different from any future results expressed or
implied by such forward-looking statements. Information identifying
such important factors is contained under “Risk Factors” in
Lexicon’s annual report on Form 10-K for the year ended December
31, 2023 and other subsequent disclosure documents filed with the
Securities and Exchange Commission. Lexicon undertakes no
obligation to update or revise any such forward-looking statements,
whether as a result of new information, future events or
otherwise.
For Investor
Inquiries:
Lisa DeFrancescoLexicon Pharmaceuticals,
Inc.lexinvest@lexpharma.com
For Media Inquiries:
Alina Cocuzza Lexicon Pharmaceuticals,
Inc. acocuzza@lexpharma.com
Lexicon Pharmaceuticals (NASDAQ:LXRX)
Graphique Historique de l'Action
De Mai 2024 à Juin 2024
Lexicon Pharmaceuticals (NASDAQ:LXRX)
Graphique Historique de l'Action
De Juin 2023 à Juin 2024